Aflibercept biosimilar - Qilu Pharmaceutical
Alternative Names: QL1207Latest Information Update: 13 Jun 2022
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
- Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Wet age-related macular degeneration
Most Recent Events
- 25 Jan 2022 Qilu Pharmaceutical completes a Phase III trial in Wet age-related macular degeneration (In adults, In the elderly) in China (Intravitreous) (NCT05345236)
- 19 Aug 2019 Phase III clinical trial in Wet age-related macular degeneration (In adults, In the elderly) in China (Intravitreous) (NCT05345236)